<?xml version="1.0" encoding="utf-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hal="http://hal.archives-ouvertes.fr/" xmlns:gml="http://www.opengis.net/gml/3.3/" xmlns:gmlce="http://www.opengis.net/gml/3.3/ce" version="1.1" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 http://api.archives-ouvertes.fr/documents/aofr-sword.xsd">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>HAL TEI export of hal-04167336</title>
      </titleStmt>
      <publicationStmt>
        <distributor>CCSD</distributor>
        <availability status="restricted">
          <licence target="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 - Universal</licence>
        </availability>
        <date when="2026-05-06T11:41:05+02:00"/>
      </publicationStmt>
      <sourceDesc>
        <p part="N">HAL API Platform</p>
      </sourceDesc>
    </fileDesc>
  </teiHeader>
  <text>
    <body>
      <listBibl>
        <biblFull>
          <titleStmt>
            <title xml:lang="en">Covalent-reversible peptide-based protease inhibitors. Design, synthesis, and clinical success stories</title>
            <author role="aut">
              <persName>
                <forename type="first">Anthony</forename>
                <surname>Feral</surname>
              </persName>
              <email type="md5">4a8a6e4ec74cfb37c5d2874fa6a25d47</email>
              <email type="domain">umontpellier.fr</email>
              <idno type="idhal" notation="string">anthonyferal</idno>
              <idno type="idhal" notation="numeric">1268179</idno>
              <idno type="halauthorid" notation="string">2112388-1268179</idno>
              <idno type="RESEARCHERID">http://www.researcherid.com/rid/HPD-3569-2023</idno>
              <affiliation ref="#struct-1100660"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Anthony R.</forename>
                <surname>Martin</surname>
              </persName>
              <email type="md5">54ffc9e03839b8f2a53140d22ad72973</email>
              <email type="domain">cnrs.fr</email>
              <idno type="idhal" notation="string">amartin</idno>
              <idno type="idhal" notation="numeric">739044</idno>
              <idno type="halauthorid" notation="string">9233-739044</idno>
              <idno type="RESEARCHERID">http://www.researcherid.com/rid/D-4158-2013</idno>
              <idno type="ORCID">https://orcid.org/0000-0001-6187-6979</idno>
              <idno type="IDREF">https://www.idref.fr/158149009</idno>
              <idno type="RESEARCHERID">http://www.researcherid.com/rid/http://www.researcherid.com/rid/D-4158-2013</idno>
              <affiliation ref="#struct-1100660"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Alexandre</forename>
                <surname>Desfoux</surname>
              </persName>
              <idno type="idhal" notation="numeric">1271809</idno>
              <idno type="halauthorid" notation="string">2165570-1271809</idno>
              <idno type="ORCID">https://orcid.org/0009-0006-7058-4197</idno>
              <affiliation ref="#struct-1100660"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Muriel</forename>
                <surname>Amblard</surname>
              </persName>
              <email type="md5">1b64e86bc3cc1d8908b9403a704201f8</email>
              <email type="domain">umontpellier.fr</email>
              <idno type="idhal" notation="string">muriehal</idno>
              <idno type="idhal" notation="numeric">741517</idno>
              <idno type="halauthorid" notation="string">3794-741517</idno>
              <idno type="ORCID">https://orcid.org/0000-0001-8922-1755</idno>
              <idno type="IDREF">https://www.idref.fr/099420511</idno>
              <affiliation ref="#struct-1100660"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Lubomir</forename>
                <surname>Vezenkov</surname>
              </persName>
              <email type="md5">f1e0c2854548a7d2f42e81e7ade22f4a</email>
              <email type="domain">enscm.fr</email>
              <idno type="idhal" notation="string">lubomir-vezenkov</idno>
              <idno type="idhal" notation="numeric">1271810</idno>
              <idno type="halauthorid" notation="string">1154809-1271810</idno>
              <idno type="ORCID">https://orcid.org/0000-0001-6348-7985</idno>
              <idno type="IDREF">https://www.idref.fr/152228667</idno>
              <affiliation ref="#struct-1100660"/>
            </author>
            <editor role="depositor">
              <persName>
                <forename>Anthony</forename>
                <surname>Martin</surname>
              </persName>
              <email type="md5">54ffc9e03839b8f2a53140d22ad72973</email>
              <email type="domain">cnrs.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>
            <edition n="v1" type="current">
              <date type="whenSubmitted">2023-07-20 15:55:33</date>
              <date type="whenModified">2024-11-07 16:14:03</date>
              <date type="whenReleased">2023-07-20 16:03:28</date>
              <date type="whenProduced">2023</date>
              <date type="whenEndEmbargoed">2023-07-20</date>
              <ref type="file" target="https://hal.science/hal-04167336v1/document">
                <date notBefore="2023-07-20"/>
              </ref>
              <ref type="file" subtype="author" n="1" target="https://hal.science/hal-04167336v1/file/HAL_Covalent-reversible%20peptide-based%20proteases%20inhibitors.%20Design%2C%20synthe...tories.pdf" id="file-4167336-3629484">
                <date notBefore="2023-07-20"/>
              </ref>
            </edition>
            <respStmt>
              <resp>contributor</resp>
              <name key="345646">
                <persName>
                  <forename>Anthony</forename>
                  <surname>Martin</surname>
                </persName>
                <email type="md5">54ffc9e03839b8f2a53140d22ad72973</email>
                <email type="domain">cnrs.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>
            <distributor>CCSD</distributor>
            <idno type="halId">hal-04167336</idno>
            <idno type="halUri">https://hal.science/hal-04167336</idno>
            <idno type="halBibtex">feral:hal-04167336</idno>
            <idno type="halRefHtml">&lt;i&gt;Amino Acids&lt;/i&gt;, In press, &lt;a target="_blank" href="https://dx.doi.org/10.1007/s00726-023-03286-1"&gt;&amp;#x27E8;10.1007/s00726-023-03286-1&amp;#x27E9;&lt;/a&gt;</idno>
            <idno type="halRef">Amino Acids, In press, &amp;#x27E8;10.1007/s00726-023-03286-1&amp;#x27E9;</idno>
            <availability status="restricted">
              <licence target="https://about.hal.science/hal-authorisation-v1/">HAL Authorization<ref corresp="#file-4167336-3629484"/></licence>
            </availability>
          </publicationStmt>
          <seriesStmt>
            <idno type="stamp" n="CNRS">CNRS - Centre national de la recherche scientifique</idno>
            <idno type="stamp" n="ENSC-MONTPELLIER">Ecole Nationale Supérieure de Chimie de Montpellier</idno>
            <idno type="stamp" n="IBMM">Institut des Biomolécules Max Mousseron</idno>
            <idno type="stamp" n="INC-CNRS">Institut de Chimie du CNRS</idno>
            <idno type="stamp" n="CHIMIE">Chimie</idno>
            <idno type="stamp" n="UNIV-MONTPELLIER">Université de Montpellier</idno>
            <idno type="stamp" n="UM-2015-2021" corresp="UNIV-MONTPELLIER">Université de Montpellier (2015-2021)</idno>
            <idno type="stamp" n="UM-EPE" corresp="UNIV-MONTPELLIER">Université de Montpellier - EPE</idno>
          </seriesStmt>
          <notesStmt>
            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>
            <biblStruct>
              <analytic>
                <title xml:lang="en">Covalent-reversible peptide-based protease inhibitors. Design, synthesis, and clinical success stories</title>
                <author role="aut">
                  <persName>
                    <forename type="first">Anthony</forename>
                    <surname>Feral</surname>
                  </persName>
                  <email type="md5">4a8a6e4ec74cfb37c5d2874fa6a25d47</email>
                  <email type="domain">umontpellier.fr</email>
                  <idno type="idhal" notation="string">anthonyferal</idno>
                  <idno type="idhal" notation="numeric">1268179</idno>
                  <idno type="halauthorid" notation="string">2112388-1268179</idno>
                  <idno type="RESEARCHERID">http://www.researcherid.com/rid/HPD-3569-2023</idno>
                  <affiliation ref="#struct-1100660"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Anthony R.</forename>
                    <surname>Martin</surname>
                  </persName>
                  <email type="md5">54ffc9e03839b8f2a53140d22ad72973</email>
                  <email type="domain">cnrs.fr</email>
                  <idno type="idhal" notation="string">amartin</idno>
                  <idno type="idhal" notation="numeric">739044</idno>
                  <idno type="halauthorid" notation="string">9233-739044</idno>
                  <idno type="RESEARCHERID">http://www.researcherid.com/rid/D-4158-2013</idno>
                  <idno type="ORCID">https://orcid.org/0000-0001-6187-6979</idno>
                  <idno type="IDREF">https://www.idref.fr/158149009</idno>
                  <idno type="RESEARCHERID">http://www.researcherid.com/rid/http://www.researcherid.com/rid/D-4158-2013</idno>
                  <affiliation ref="#struct-1100660"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Alexandre</forename>
                    <surname>Desfoux</surname>
                  </persName>
                  <idno type="idhal" notation="numeric">1271809</idno>
                  <idno type="halauthorid" notation="string">2165570-1271809</idno>
                  <idno type="ORCID">https://orcid.org/0009-0006-7058-4197</idno>
                  <affiliation ref="#struct-1100660"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Muriel</forename>
                    <surname>Amblard</surname>
                  </persName>
                  <email type="md5">1b64e86bc3cc1d8908b9403a704201f8</email>
                  <email type="domain">umontpellier.fr</email>
                  <idno type="idhal" notation="string">muriehal</idno>
                  <idno type="idhal" notation="numeric">741517</idno>
                  <idno type="halauthorid" notation="string">3794-741517</idno>
                  <idno type="ORCID">https://orcid.org/0000-0001-8922-1755</idno>
                  <idno type="IDREF">https://www.idref.fr/099420511</idno>
                  <affiliation ref="#struct-1100660"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Lubomir</forename>
                    <surname>Vezenkov</surname>
                  </persName>
                  <email type="md5">f1e0c2854548a7d2f42e81e7ade22f4a</email>
                  <email type="domain">enscm.fr</email>
                  <idno type="idhal" notation="string">lubomir-vezenkov</idno>
                  <idno type="idhal" notation="numeric">1271810</idno>
                  <idno type="halauthorid" notation="string">1154809-1271810</idno>
                  <idno type="ORCID">https://orcid.org/0000-0001-6348-7985</idno>
                  <idno type="IDREF">https://www.idref.fr/152228667</idno>
                  <affiliation ref="#struct-1100660"/>
                </author>
              </analytic>
              <monogr>
                <idno type="halJournalId" status="VALID">10415</idno>
                <idno type="issn">0939-4451</idno>
                <idno type="eissn">1438-2199</idno>
                <title level="j">Amino Acids</title>
                <imprint>
                  <publisher>Springer Verlag</publisher>
                  <date type="datePub" subtype="inPress">2023</date>
                  <date type="dateEpub">2023-06-17</date>
                </imprint>
              </monogr>
              <idno type="doi">10.1007/s00726-023-03286-1</idno>
            </biblStruct>
          </sourceDesc>
          <profileDesc>
            <langUsage>
              <language ident="en">English</language>
            </langUsage>
            <textClass>
              <keywords scheme="author">
                <term xml:lang="en">Enzymes</term>
                <term xml:lang="en">Proteases</term>
                <term xml:lang="en">Drug discovery</term>
                <term xml:lang="en">Covalent-reversible inhibitors</term>
                <term xml:lang="en">Covalent inhibitors</term>
                <term xml:lang="en">Peptides</term>
              </keywords>
              <classCode scheme="halDomain" n="chim.ther">Chemical Sciences/Medicinal Chemistry</classCode>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halOldTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halTreeTypology" n="ART.ARTREV">Journal articles - Review article</classCode>
            </textClass>
            <abstract xml:lang="en">
              <p>Dysregulated human peptidases are implicated in a large variety of diseases such as cancer, hypertension, and neurodegeneration. Viral proteases for their part are crucial for the pathogens' maturation and assembly. Several decades of research were devoted to exploring these precious therapeutic targets, often addressing them with synthetic substrate-based inhibitors to elucidate their biological roles and develop medications. The rational design of peptide-based inhibitors offered a rapid pathway to obtain a variety of research tools and drug candidates. Non-covalent modifiers were historically the first choice for protease inhibition due to their reversible enzyme binding mode and thus presumably safer profile. However, in recent years, covalentirreversible inhibitors are having a resurgence with dramatic increase of their related publications, preclinical and clinical trials, and FDA approved drugs. Depending on the context, covalent modifiers could provide more effective and selective drug candidates, hence requiring lower doses, thereby limiting off-target effects. Additionally, such molecules seem more suitable to tackle the crucial issue of cancer and viral drug resistances. At the frontier of reversible and irreversible based inhibitors, a new drug class, the covalent-reversible peptidebased inhibitors, has emerged with the FDA approval of Bortezomib in 2003, shortly followed by 4 other listings to date. The highlight in the field is the breathtakingly fast development of the first oral COVID-19 medication, Nirmatrelvir. Covalent-reversible inhibitors can theoretically provide the safety of the reversible modifiers combined with the high potency and specificity of their irreversible counterparts. Herein, we will present the main groups of covalent-reversible peptide-based inhibitors, focusing on their design, synthesis, and successful drug development programs.</p>
            </abstract>
          </profileDesc>
        </biblFull>
      </listBibl>
    </body>
    <back>
      <listOrg type="structures">
        <org type="laboratory" xml:id="struct-1100660" status="VALID">
          <idno type="RNSR">200711912X</idno>
          <idno type="ROR">https://ror.org/05d1e6v30</idno>
          <orgName>Institut des Biomolécules Max Mousseron [Pôle Chimie Balard]</orgName>
          <orgName type="acronym">IBMM</orgName>
          <date type="start">2022-01-01</date>
          <desc>
            <address>
              <addrLine>CNRS - 1919 Route de Mende34293 Montpellier cedex 5</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.ibmm.univ-montp1.fr</ref>
          </desc>
          <listRelation>
            <relation active="#struct-341038" type="direct"/>
            <relation name="UMR5247" active="#struct-441569" type="direct"/>
            <relation active="#struct-1100589" type="direct"/>
            <relation active="#struct-1100619" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-341038" status="VALID">
          <idno type="IdRef">232435103</idno>
          <idno type="ISNI">000000010626358X</idno>
          <idno type="ROR">https://ror.org/02cte4b68</idno>
          <orgName>Institut de Chimie - CNRS Chimie</orgName>
          <orgName type="acronym">INC-CNRS</orgName>
          <date type="start">2009-10-01</date>
          <desc>
            <address>
              <addrLine>CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE3 rue Michel-Ange75794 PARIS CEDEX 16 - France</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.cnrs.fr/inc</ref>
          </desc>
        </org>
        <org type="regroupinstitution" xml:id="struct-441569" status="VALID">
          <idno type="IdRef">02636817X</idno>
          <idno type="ISNI">0000000122597504</idno>
          <idno type="ROR">https://ror.org/02feahw73</idno>
          <orgName>Centre National de la Recherche Scientifique</orgName>
          <orgName type="acronym">CNRS</orgName>
          <date type="start">1939-10-19</date>
          <desc>
            <address>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.cnrs.fr/</ref>
          </desc>
        </org>
        <org type="regroupinstitution" xml:id="struct-1100589" status="VALID">
          <idno type="ROR">https://ror.org/051escj72</idno>
          <orgName>Université de Montpellier</orgName>
          <orgName type="acronym">UM</orgName>
          <date type="start">2022-01-01</date>
          <desc>
            <address>
              <addrLine>163 rue Auguste Broussonnet - 34090 Montpellier</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.umontpellier.fr/</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-1100619" status="VALID">
          <idno type="ROR">https://ror.org/03sgyqj04</idno>
          <orgName>Ecole Nationale Supérieure de Chimie de Montpellier</orgName>
          <orgName type="acronym">ENSCM</orgName>
          <date type="start">2022-01-01</date>
          <desc>
            <address>
              <addrLine>8 Rue de l'Ecole Normale 34296 Montpellier Cedex 5</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.enscm.fr</ref>
          </desc>
          <listRelation>
            <relation active="#struct-1100589" type="direct"/>
          </listRelation>
        </org>
      </listOrg>
    </back>
  </text>
</TEI>